Cardiovascular Diseases
At Hopital Prive Saint Claude the gastroenterology department is also conducting a study focused on heart failure with concurrent kidney impairment, aiming to test whether adding balcinrenone/dapagliflozin can lower the risk of cardiovascular death and related hospitalizations.
- Comparison of combination therapy versus standard dapagliflozin alone
- Assessment of reduction in heart‑failure events
- Evaluation of safety in patients with reduced kidney function
The trial involves two investigators and reflects the site’s commitment to advancing treatments for complex cardiovascular conditions.
Digestive System Diseases
Researchers are exploring a ctDNA‑guided adjuvant approach for stage II colon carcinoma, seeking to improve disease‑free survival by treating patients who test positive for circulating tumor DNA with FOLFOX6m chemotherapy.
- Use of circulating tumor DNA to personalize adjuvant therapy
- Targeted administration of intensified FOLFOX regimen
- Monitoring of recurrence risk after surgery
This study highlights the site’s innovative focus on molecular diagnostics within digestive oncology.
Neoplasms
A separate trial evaluates first‑line treatment of microsatellite stable metastatic colorectal cancer with a high immune infiltrate, combining pembrolizumab immunotherapy with XELOX or FOLFOX chemotherapy and bevacizumab to increase the proportion of patients alive without disease progression at ten months.
- Integration of immunotherapy with standard chemotherapy
- Stratification based on tumor immune infiltrate
- Measurement of 10‑month progression‑free survival
The project underscores the collaborative effort of the site’s investigators to bring novel combination regimens to patients with advanced colorectal cancer.
